MUKESH SANGHADIA: Open Payments
NPI 1366550246 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$17,023 in 26 payments from 7 companies in 2025. Trend: 2023 $23,372 · 2024 $45,493 · 2025 $17,023
Speaker / faculty: $10,940Consulting: $5,060Food & beverage: $985Travel & lodging: $38
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 15 | $10,319 |
| Teva Pharmaceuticals USA, Inc. | 6 | $6,325 |
| Alkermes, Inc. | 1 | $121 |
| Neurelis, Inc. | 1 | $118 |
| Janssen Pharmaceuticals, Inc | 1 | $93 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
Products named: INGREZZA, UZEDY, AUSTEDO XR, LYBALVI, VALTOCO, INVEGA SUSTENNA, FANAPT, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
